BiotechTube
Synexa Life Sciences

Synexa Life Sciences

Leiden, Netherlands· Est.
synexagroup.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Synexa Life Sciences is a specialized, full-service biomarker and bioanalytical CRO with over two decades of experience. It provides end-to-end assay development and sample analysis services to biopharma clients, leveraging deep scientific expertise across multiple technology platforms to de-risk and accelerate therapeutic pipelines. With a team of over 200 staff, including a high proportion of scientists, and a global laboratory footprint, the company positions itself as a collaborative partner for complex bioanalytical challenges in clinical trials and translational research.

DiagnosticsBiologics

Technology Platform

Integrated bioanalytical service platform encompassing immunoassays (MSD, ELISA), LC-MS/MS, high-parameter flow cytometry, genomics (qPCR, ddPCR), proteomics (Olink PEA), spatial biology/tissue imaging, and specialized radiopharmaceutical analysis. Not a single proprietary technology, but deep expertise in validating and applying multiple complex assay platforms.

Funding History

2
Total raised:$17.5M
Series B$12M
Series A$5.5M

Opportunities

Growth is driven by the increasing complexity of new drug modalities (biologics, cell therapies, radiopharmaceuticals) which require specialized bioanalytical support.
The rising importance of biomarker-driven development and personalized medicine expands demand for its core biomarker identification and validation services.
The niche radiopharmaceutical bioanalysis market offers high-growth potential with limited competition.

Risk Factors

Revenue is tied to biopharma R&D spending, which is cyclical and sensitive to economic conditions.
The company faces intense competition from both large, full-service CROs and other niche specialists.
Operational risks include maintaining data integrity and regulatory compliance across global sites, as any failure could severely damage its reputation.

Competitive Landscape

Synexa competes in the specialized biomarker and complex bioanalysis segment of the larger CRO market. Key competitors include large players with specialized divisions (e.g., LabCorp's Covance, IQVIA) and focused niche CROs (e.g., SGS, Q2 Solutions, BioAgilytix). Its differentiation lies in its broad, integrated platform, specific expertise in high-parameter flow cytometry and radiopharmaceuticals, and a consultative, scientist-led approach.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →